Long-term effectiveness and safety of endoxifen in the treatment of bipolar mania: a case report

Abstract

Bipolar disorder (BD) displays abnormalities in protein kinase C (PKC) signaling, and evidence suggests that inhibiting PKC may help treat mania. Endoxifen a potent inhibitor of the PKC signaling pathway, is effective in controlling acute bipolar mania, at doses of 8 mg OD, for a period of 3-weeks. Here we present the case of a patient with severe mania, increased alcohol consumption administered endoxifen 8 mg BID for a period of 3-months, to achieve a better response. High-dose, long-term treatment with endoxifen was efficacious in controlling manic symptoms, with no adverse effects. Additionally, the patient didn’t consume alcohol during the course of treatment. This case showed the long-term effectiveness and safety of high-dose endoxifen to control mania in a patient with BD.

Real-World Long-Term Experience on Endoxifen in Bipolar Disorder with Psychotic Symptoms

“…Recently, a case of a 52-year-old patient with severe mania reported long-term safety and effectiveness of 8 mg BID endoxifen for 3 months. During the treatment, the patient was also de-addicted from his alcohol addiction [ 16 ]. Psychostimulants, which can trigger manic episodes in susceptible persons, are known to activate PKC [ 17 ].…”